Filing Flows › Impact Biomedical (IBO) › Q4 2025
Impact Biomedical (IBO) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 11, 2026
Impact Biomedical (IBO) reported revenue of $7K for the fourth quarter 2025 (Q4 2025) and -61% from the quarter before.
Impact Biomedical, Q4 2025: revenue $7K, net earnings $5.2M, operating cash flow $99K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7K | -61% | — |
| Operating profit | −$1.2M | — | — |
| Net earnings | $5.2M | — | — |
| Operating cash flow | $99K | — | — |
What changed
Revenue was $7K in Q4 2025, down 61% from the previous quarter.
Operating costs exceeded revenue by $1.2M, an operating margin of -16714.3%. Net earnings were $5.2M ($5.2M including minority interests, which bore $10K of losses). The effective tax rate was -97.2%. Non-operating items added $3.8M, 144% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $99K, 2% of net earnings. Non-cash charges added back $286K of depreciation and amortization and $8K of share-based compensation. Working capital and other items used $5.4M.
Questions
What was Impact Biomedical's revenue in the fourth quarter 2025?
Impact Biomedical (IBO) reported revenue of $7K for the fourth quarter 2025 (Q4 2025) and -61% from the quarter before.
Source: Impact Biomedical 10-K on SEC EDGAR.